Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Advanced Cancer|Metastatic Cancer|Malignant Neoplastic Disease
DRUG: MRTX849|DRUG: Pembrolizumab|DRUG: Cetuximab|DRUG: Afatinib
Characterize the safety of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation, Number of participants with treatment related adverse events, 20 months|Evaluate the pharmacokinetics of MRTX849, Blood plasma concentration, 20 months|Evaluate clinical activity/efficacy of MRTX849, Objective response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST), 20 months
Establish maximum tolerated dose, Number of participants with dose limiting toxicity, 12 months|Characterize safety and tolerability of MRTX849 in combination with selected therapeutic agents, Number of participants with dose limiting toxicity, 12 months|Evaluate the pharmacokinetics of new MRTX849 oral formulations, Blood plasma concentration, 6 months|Evaluate the pharmacokinetics of MRTX849 administered with food, Blood plasma concentration, 6 months
This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.